Plain-English translation of NCT07543055 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called BPX-601, which is made from your own immune cells and designed to fight prostate cancer cells. Researchers want to find the right dose of this medication and learn what side effects it might cause. This is an early-stage study to see whether this treatment could help men with advanced prostate cancer that has stopped responding to other medicines.
Prostate cancer that has spread and become resistant to standard treatments is very difficult to manage, and men who reach this stage have limited options. This trial exists to see if using a patient's own immune cells could offer a new way to fight this aggressive form of cancer.
You likely qualify if…
You likely don't qualify if…
You would have your immune cells collected through a process similar to a blood draw, and the cells would be sent to a laboratory to be grown and modified into the study medication. After the cells are ready, you would receive an infusion of the treatment at the study center. The study involves regular visits for blood tests, scans, and checkups to monitor how you respond to the treatment and track any side effects.
AI-generated summary from trial data · Aug 25, 2026 · Not medical advice
United States